These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 31802121)

  • 1. Hybridization-mediated off-target effects of splice-switching antisense oligonucleotides.
    Scharner J; Ma WK; Zhang Q; Lin KT; Rigo F; Bennett CF; Krainer AR
    Nucleic Acids Res; 2020 Jan; 48(2):802-816. PubMed ID: 31802121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of cryptic pre-mRNA splice-switching by antisense oligonucleotides.
    Ham KA; Keegan NP; McIntosh CS; Aung-Htut MT; Zaw K; Greer K; Fletcher S; Wilton SD
    Sci Rep; 2021 Jul; 11(1):15137. PubMed ID: 34302060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimated number of off-target candidate sites for antisense oligonucleotides in human mRNA sequences.
    Yoshida T; Naito Y; Sasaki K; Uchida E; Sato Y; Naito M; Kawanishi T; Obika S; Inoue T
    Genes Cells; 2018 Jun; 23(6):448-455. PubMed ID: 29667281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic oligonucleotides recruit ILF2/3 to RNA transcripts to modulate splicing.
    Rigo F; Hua Y; Chun SJ; Prakash TP; Krainer AR; Bennett CF
    Nat Chem Biol; 2012 Apr; 8(6):555-61. PubMed ID: 22504300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining the factors that contribute to on-target specificity of antisense oligonucleotides.
    Lima WF; Vickers TA; Nichols J; Li C; Crooke ST
    PLoS One; 2014; 9(7):e101752. PubMed ID: 25072142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repair of aberrant splicing in growth hormone receptor by antisense oligonucleotides targeting the splice sites of a pseudoexon.
    David A; Srirangalingam U; Metherell LA; Khoo B; Clark AJ
    J Clin Endocrinol Metab; 2010 Jul; 95(7):3542-6. PubMed ID: 20427506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of combinations of gapmer antisense oligonucleotides on the target reduction.
    Yanagidaira M; Yoshioka K; Nagata T; Nakao S; Miyata K; Yokota T
    Mol Biol Rep; 2023 Apr; 50(4):3539-3546. PubMed ID: 36787053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of the regulatory effects of synthesized antisense oligonucleotides on androgen receptor (AR) exon 3 splicing in prostate cancer cells.
    Wang L; Gong S; Zhang X; Azhar Z; Chen J
    Gene; 2023 May; 866():147330. PubMed ID: 36871670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense-mediated exon inclusion.
    Hua Y; Krainer AR
    Methods Mol Biol; 2012; 867():307-23. PubMed ID: 22454070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consensus Guidelines for the Design and
    Aartsma-Rus A; Garanto A; van Roon-Mom W; McConnell EM; Suslovitch V; Yan WX; Watts JK; Yu TW
    Nucleic Acid Ther; 2023 Jan; 33(1):17-25. PubMed ID: 36516128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Antisense Oligonucleotide against a Splicing Enhancer Sequence within Exon 1 of the
    Maeta K; Farea M; Nishio H; Matsuo M
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear antisense effects in cyclophilin A pre-mRNA splicing by oligonucleotides: a comparison of tricyclo-DNA with LNA.
    Ittig D; Liu S; Renneberg D; Schümperli D; Leumann CJ
    Nucleic Acids Res; 2004; 32(1):346-53. PubMed ID: 14726483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-mRNA Splicing Modulation by Antisense Oligonucleotides.
    Singh NN; Luo D; Singh RN
    Methods Mol Biol; 2018; 1828():415-437. PubMed ID: 30171557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational Design of Chimeric Antisense Oligonucleotides on a Mixed PO-PS Backbone for Splice-Switching Applications.
    Le BT; Chen S; Veedu RN
    Biomolecules; 2024 Jul; 14(7):. PubMed ID: 39062597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity of splice sites to antisense oligonucleotides in vivo.
    Sierakowska H; Sambade MJ; Schümperli D; Kole R
    RNA; 1999 Mar; 5(3):369-77. PubMed ID: 10094306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A framework for individualized splice-switching oligonucleotide therapy.
    Kim J; Woo S; de Gusmao CM; Zhao B; Chin DH; DiDonato RL; Nguyen MA; Nakayama T; Hu CA; Soucy A; Kuniholm A; Thornton JK; Riccardi O; Friedman DA; El Achkar CM; Dash Z; Cornelissen L; Donado C; Faour KNW; Bush LW; Suslovitch V; Lentucci C; Park PJ; Lee EA; Patterson A; Philippakis AA; Margus B; Berde CB; Yu TW
    Nature; 2023 Jul; 619(7971):828-836. PubMed ID: 37438524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of off-target effects of gapmer antisense oligonucleotides using human cells.
    Yoshida T; Naito Y; Yasuhara H; Sasaki K; Kawaji H; Kawai J; Naito M; Okuda H; Obika S; Inoue T
    Genes Cells; 2019 Dec; 24(12):827-835. PubMed ID: 31637814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus.
    Liang XH; Sun H; Nichols JG; Crooke ST
    Mol Ther; 2017 Sep; 25(9):2075-2092. PubMed ID: 28663102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exonic splicing enhancers contribute to the use of both 3' and 5' splice site usage of rat beta-tropomyosin pre-mRNA.
    Selvakumar M; Helfman DM
    RNA; 1999 Mar; 5(3):378-94. PubMed ID: 10094307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides.
    Ward AJ; Norrbom M; Chun S; Bennett CF; Rigo F
    Nucleic Acids Res; 2014 May; 42(9):5871-9. PubMed ID: 24589581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.